152 related articles for article (PubMed ID: 31926048)
1. Simultaneous development of Graves' disease and type 1 diabetes during anti-programmed cell death-1 therapy: A case report.
Kurihara S; Oikawa Y; Nakajima R; Satomura A; Tanaka R; Kagamu H; Shimada A
J Diabetes Investig; 2020 Jul; 11(4):1006-1009. PubMed ID: 31926048
[TBL] [Abstract][Full Text] [Related]
2. New-onset graves' disease after the initiation of nivolumab therapy for gastric cancer: a case report.
Yamada H; Okajima F; Onda T; Fujimori S; Emoto N; Sugihara H
BMC Endocr Disord; 2020 Aug; 20(1):132. PubMed ID: 32847555
[TBL] [Abstract][Full Text] [Related]
3. A case of type 1 diabetes onset and recurrence of Graves' disease during pegylated interferon-α plus ribavirin treatment for chronic hepatitis C.
Fujioka T; Honda M; Yoshizaki T; Ogawa M; Matsuno H; Shimokawa K; Koyama K
Intern Med; 2010; 49(18):1987-90. PubMed ID: 20847504
[TBL] [Abstract][Full Text] [Related]
4. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
Yilmaz M
J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
[TBL] [Abstract][Full Text] [Related]
6. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy.
Okamoto M; Okamoto M; Gotoh K; Masaki T; Ozeki Y; Ando H; Anai M; Sato A; Yoshida Y; Ueda S; Kakuma T; Shibata H
J Diabetes Investig; 2016 Nov; 7(6):915-918. PubMed ID: 27181090
[TBL] [Abstract][Full Text] [Related]
7. Aggravation of diabetes, and incompletely deficient insulin secretion in a case with type 1 diabetes-resistant human leukocyte antigen DRB1*15:02 treated with nivolumab.
Matsumura K; Nagasawa K; Oshima Y; Kikuno S; Hayashi K; Nishimura A; Okubo M; Uruga H; Kishi K; Kobayashi T; Mori Y
J Diabetes Investig; 2018 Mar; 9(2):438-441. PubMed ID: 28418115
[TBL] [Abstract][Full Text] [Related]
8. Graves' disease coexisted with resistance to thyroid hormone: a case report.
Akahori H; Usuda R
J Med Case Rep; 2021 Sep; 15(1):473. PubMed ID: 34560890
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous occurrence of subacute thyroiditis and Graves' disease.
Hoang TD; Mai VQ; Clyde PW; Shakir MK
Thyroid; 2011 Dec; 21(12):1397-400. PubMed ID: 22136271
[TBL] [Abstract][Full Text] [Related]
10. A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia.
Yamamoto N; Tsurutani Y; Katsuragawa S; Kubo H; Sunouchi T; Hirose R; Hoshino Y; Ichikawa M; Takiguchi T; Yukawa H; Arioka H; Saitou J; Nishikawa T
Intern Med; 2019 Oct; 58(19):2825-2830. PubMed ID: 31243198
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
12. [Immune checkpoint inhibitors and endocrinological side effects].
Jørgensen LB; Bastholt L; Yderstræde K
Ugeskr Laeger; 2017 Dec; 179(49):. PubMed ID: 29212592
[TBL] [Abstract][Full Text] [Related]
13. Idiopathic thrombocytopenic purpura subsequent to Graves' disease and insulin-dependent diabetes mellitus.
Yamaguchi K; Ookubo Y; Matsuda H; Suzaki K; Fukushima H; Uzawa H
Diabetes Res Clin Pract; 1987; 3(4):233-7. PubMed ID: 3622224
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous occurrence of type 1 diabetes mellitus and Graves' disease: a report of two cases and a review of the literature.
Mizokami T; Yamauchi A; Sato Y; Toyonaga M; Imoto H; Kojima H; Saji H; Nunoi K
Intern Med; 2013; 52(22):2537-43. PubMed ID: 24240794
[TBL] [Abstract][Full Text] [Related]
15. New HLA DRB1 and DQB1 haplotypes in a pedigree of familial Graves' disease in Japan.
Sasaki M; Yuzawa M; Saito T; Ikoma A; Tamemoto H; Kawakami M; Ishikawa SE
Endocr J; 2007 Dec; 54(5):721-5. PubMed ID: 17785916
[TBL] [Abstract][Full Text] [Related]
16. Thyrotropin-producing pituitary adenoma simultaneously existing with Graves' disease: a case report.
Arai N; Inaba M; Ichijyo T; Kagami H; Mine Y
J Med Case Rep; 2017 Jan; 11(1):9. PubMed ID: 28061802
[TBL] [Abstract][Full Text] [Related]
17. Rapid onset type-1 diabetes and diabetic ketoacidosis secondary to nivolumab immunotherapy: a review of existing literature.
Abdullah HMA; Elnair R; Khan UI; Omar M; Morey-Vargas OL
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31451458
[TBL] [Abstract][Full Text] [Related]
18. HLA typing of patients who developed subacute thyroiditis and Graves' disease after SARS-CoV-2 vaccination: a case report.
Yasuda S; Suzuki S; Yanagisawa S; Morita H; Haisa A; Satomura A; Nakajima R; Oikawa Y; Inoue I; Shimada A
BMC Endocr Disord; 2023 Mar; 23(1):54. PubMed ID: 36879263
[TBL] [Abstract][Full Text] [Related]
19. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab-induced acute-onset type 1 diabetes mellitus as an immune-related adverse event: A case report.
Hatakeyama Y; Ohnishi H; Suda K; Okamura K; Shimada T; Yoshimura S
J Oncol Pharm Pract; 2019 Dec; 25(8):2023-2026. PubMed ID: 30526346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
